A recent report by Lee et al. also assessed the incidence of RAS/RAF alterations among patients with HER2-amplified CRC as a single institutional experience by using pathology reports from a South Korean hospital.12 This report noted a HER2 amplification incidence of 4.1%, notably higher than the 2.6% HER2 amplification incidence in our present study, likely due to demographic differences. The gene discussed is ERBB2; the disease is colorectal carcinoma.